Finally, the results showed that there were significant differences in CD80, CD48, IDO2, CD276, CD28, and CD200R1 between both groups, which could be used as potential therapeutic targets for the treatment of nephroblastoma. The gene discussed is IDO2; the disease is Nephroblastoma.